Literature DB >> 20484558

Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.

Masanao Nakashima1, John S Lazo.   

Abstract

The phosphatases of regenerating liver (PRLs) are a unique family of plasma membrane-associated protein tyrosine phosphatases that have been hypothesized to be involved in metastatic cancer. How PRLs control cancer cell migration, invasion, and proliferation remains largely unknown. In the current study, we demonstrate a role for PRL-1 in the regulation of filamentous actin dynamics, which could promote cell metastatic processes. Human A549 non-small-cell lung cancer cells stably expressing wild-type PRL-1 exhibited a 60% increase in migration and a 3-fold increase in invasion. Cells expressing catalytic mutants of PRL-1 (C104S and D72A) lacked increased cell migration and invasion, indicating that these phenotypic changes required PRL-1 phosphatase activity. In contrast, PRL-1 small interfering RNA decreased in vitro lung cancer cell migration and invasion. The cadherin-catenin complex and dynamic filamentous actin are believed to control cellular invasiveness. Expression of wild-type PRL-1, but not phosphatase-inactive PRL-1 (C104S or D72A), decreased E-cadherin, vinculin, and paxillin expression. Ectopic expression of wild-type PRL-1 increased RhoA levels, which have an important role in actin filament assembly and stabilization of focal adhesion, and decreased activated Cdc42 and Rac. The Rho-associated protein kinase inhibitor, (R)-(+)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride (Y-27632), decreased RhoA activity, actin filament levels, and cellular migration and invasion in PRL-1-expressing cells. These results suggest that PRL-1 could be a productive cancer therapeutic target and support further efforts to identify its substrates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484558      PMCID: PMC2913768          DOI: 10.1124/jpet.110.167809

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome.

Authors:  Q Zeng; X Si; H Horstmann; Y Xu; W Hong; C J Pallen
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 2.  Rho and Rac take center stage.

Authors:  Keith Burridge; Krister Wennerberg
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis.

Authors:  Jing Wang; Celeste E Kirby; Ronald Herbst
Journal:  J Biol Chem       Date:  2002-09-13       Impact factor: 5.157

4.  The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity.

Authors:  Andreas Vogt; Katharine E Pestell; Billy W Day; John S Lazo; Peter Wipf
Journal:  Mol Cancer Ther       Date:  2002-09       Impact factor: 6.261

5.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases.

Authors:  T Ishizaki; M Uehata; I Tamechika; J Keel; K Nonomura; M Maekawa; S Narumiya
Journal:  Mol Pharmacol       Date:  2000-05       Impact factor: 4.436

6.  A phosphatase associated with metastasis of colorectal cancer.

Authors:  S Saha; A Bardelli; P Buckhaults; V E Velculescu; C Rago; B St Croix; K E Romans; M A Choti; C Lengauer; K W Kinzler; B Vogelstein
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

7.  The gene encoding rat insulinlike growth factor-binding protein 1 is rapidly and highly induced in regenerating liver.

Authors:  K L Mohn; A E Melby; D S Tewari; T M Laz; R Taub
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

8.  PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.

Authors:  Qi Zeng; Jing-Ming Dong; Ke Guo; Jie Li; Hui-Xian Tan; Vicki Koh; Catherine J Pallen; Edward Manser; Wanjin Hong
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

Review 9.  Rho-family GTPases: it's not only Rac and Rho (and I like it).

Authors:  Krister Wennerberg; Channing J Der
Journal:  J Cell Sci       Date:  2004-03-15       Impact factor: 5.285

10.  Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases.

Authors:  Sean R Werner; Paul A Lee; Matthew W DeCamp; Dring N Crowell; Stephen K Randall; Pamela L Crowell
Journal:  Cancer Lett       Date:  2003-12-30       Impact factor: 8.679

View more
  17 in total

1.  PRL-1 protein promotes ERK1/2 and RhoA protein activation through a non-canonical interaction with the Src homology 3 domain of p115 Rho GTPase-activating protein.

Authors:  Yunpeng Bai; Yong Luo; Sijiu Liu; Lujuan Zhang; Kui Shen; Yuanshu Dong; Chad D Walls; Lawrence A Quilliam; Clark D Wells; Youjia Cao; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

2.  Simulated microgravity inhibits the migration of mesenchymal stem cells by remodeling actin cytoskeleton and increasing cell stiffness.

Authors:  Xinjian Mao; Zhe Chen; Qing Luo; Bingyu Zhang; Guanbin Song
Journal:  Cytotechnology       Date:  2016-10-15       Impact factor: 2.058

3.  Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer.

Authors:  Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall
Journal:  Am J Transl Res       Date:  2012-01-05       Impact factor: 4.060

4.  Protein tyrosine phosphatase of liver regeneration-1 is required for normal timing of cell cycle progression during liver regeneration.

Authors:  Yang Jiao; Diana Z Ye; Zhaoyu Li; Monica Teta-Bissett; Yong Peng; Rebecca Taub; Linda E Greenbaum; Klaus H Kaestner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-11-06       Impact factor: 4.052

Review 5.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

6.  Overexpression of PTP4A1 is associated with poor overall survival in non-small cell lung cancer.

Authors:  Tao Wang; Xiaoyi Shi; Zhichao Wang; Xinyang Liu; Guoliang Zhang; Qikun Zhu; Lili Mi; Rui Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

Review 7.  Protein tyrosine phosphatases as potential therapeutic targets.

Authors:  Rong-Jun He; Zhi-Hong Yu; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

8.  Integrated analysis of global mRNA and protein expression data in HEK293 cells overexpressing PRL-1.

Authors:  Carmen M Dumaual; Boyd A Steere; Chad D Walls; Mu Wang; Zhong-Yin Zhang; Stephen K Randall
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

9.  Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells.

Authors:  Ali Flores-Pérez; Laurence A Marchat; Sergio Rodríguez-Cuevas; Verónica Piña Bautista; Lizeth Fuentes-Mera; Diana Romero-Zamora; Anabel Maciel-Dominguez; Olga Hernández de la Cruz; Miguel Fonseca-Sánchez; Erika Ruíz-García; Horacio Astudillo-de la Vega; César López-Camarillo
Journal:  BMC Cancer       Date:  2016-07-04       Impact factor: 4.430

Review 10.  Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges.

Authors:  Aneta Gandalovičová; Daniel Rosel; Michael Fernandes; Pavel Veselý; Petr Heneberg; Vladimír Čermák; Luboš Petruželka; Sunil Kumar; Victoria Sanz-Moreno; Jan Brábek
Journal:  Trends Cancer       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.